Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed director
|
|
BIOTRICITY INC. (BTCY)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/17/2023 |
8-K
| Quarterly results |
| 08/04/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 07/20/2023 |
8-K
| Quarterly results |
| 07/05/2023 |
8-K
| Quarterly results|
Docs:
|
"Biotricity Reports Business Update, Financial Results for Q4 and Full Year FY23; Company Posts Robust Revenue Growth, Overall Higher Margins, with Lower SG&A Driving Clear Path to Positive Cash Flow",
"Biotricity Announces Reverse Stock Split REDWOOD CITY, CA / ACCESSWIRE / June 30, 2023 / Biotricity Holdings, Inc. , a medical diagnostic and consumer healthcare technology company, today it will effect a reverse stock split of its common stock. Biotricity expects its common stock to begin trading on a split-adjusted basis on the Nasdaq Capital Market as of the commencement of trading on July 3, 2023." |
|
| 05/18/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits ...|
Docs:
|
"SUBSCRIPTION AGREEMENT",
"CONVERTIBLE PROMISSORY NOTE THIS NOTE AND THE SECURITIES ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, OR UNDER THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION, AND MAY NOT BE SOLD, ASSIGNED, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED OF EXCEPT IN COMPLIANCE WITH, OR PURSUANT TO AN EXEMPTION FROM, THE REQUIREMENTS OF SUCH ACT OR SUCH LAWS. BIOTRICITY INC. CONVERTIBLE PROMISSORY NOTE",
"WARRANT THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED , OR THE SECURITIES LAWS OF ANY STATE AND MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER APPLICABLE FEDERAL AND STATE SECURITIES LAWS OR PURSUANT TO AN APPLICABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, WHICH OPINION SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY. No. [__] Issue Date: [DATE] Biotricity Inc. Common Stock Purchase Warrant _________________ THIS CERTIFIES THAT, for value received, [_____] is entitled to subscribe for and purchas...",
"Cover Page Interactive Data File (embedded within the Inline XBRL document)" |
|
| 04/03/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 01/27/2023 |
8-K
| Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ... |
| 01/20/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 11/18/2022 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 08/16/2022 |
8-K
| Quarterly results |
| 08/11/2022 |
8-K
| Quarterly results |
| 07/15/2022 |
8-K
| Quarterly results |
| 05/06/2022 |
8-K
| Quarterly results |
| 03/22/2022 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 02/16/2022 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 12/28/2021 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...|
Docs:
|
"CREDIT AGREEMENT among BIOTRICITY INC., as Borrower, SWK FUNDING LLC, as Agent, Sole Lead Arranger and Sole Bookrunner, and the financial institutions party hereto from time to time as Lenders Dated as of December 21, 2021",
"WARRANT THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED , OR THE SECURITIES LAWS OF ANY STATE AND MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER APPLICABLE FEDERAL AND STATE SECURITIES LAWS OR PURSUANT TO AN APPLICABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, WHICH OPINION SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY. No. SWK – CS – 1 December 21, 2021 Biotricity Inc. Common Stock Purchase Warrant THIS CERTIFIES THAT, for value received, SWK FUNDING LLC, or its registered assigns , is entitled to...",
"GUARANTEE AND COLLATERAL AGREEMENT Guarantee and Collateral Agreement, dated as of December 21, 2021 , made by each signatory hereto , in favor of SWK Funding LLC, as administrative and collateral agent for the benefit of all Lenders party to the Credit Agreement . Agent and Lenders have severally agreed to extend credit to BIOTRICITY INC., a Nevada corporation , pursuant to the Credit Agreement . Borrower is affiliated with each other Grantor. Borrower and the other Grantors are engaged in interrelated businesses, and each Grantor will derive substantial direct and indirect benefit from extensions of credit under the Credit Agreement. It is a condition precedent to each Lender’ s obligation to extend credit under the Credit Agreement that Grantors shall have executed and delivered this Ag...",
"Schedule I" |
|
| 12/08/2021 |
8-K
| Quarterly results |
| 12/07/2021 |
8-K
| Quarterly results |
| 11/05/2021 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 09/13/2021 |
8-K
| Quarterly results |
| 09/10/2021 |
8-K
| Quarterly results |
| 08/31/2021 |
8-K
| Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits Inte...|
Docs:
|
"5,000,000 SHARES of Common Stock BIOTRICITY INC. UNDERWRITING AGREEMENT August 26, 2021 H.C. Wainwright & Co., LLC 430 Park Avenue, 3rd Floor 10022",
"UNDERWRITER COMMON STOCK PURCHASE WARRANT BIOTRICITY, INC. Warrant Shares: Initial Exercise Date: August 30, 2021 THIS UNDERWRITER COMMON STOCK PURCHASE WARRANT certifies that, for value received, or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof and on or prior to 5:00 p.m. on August 26, 2026 but not thereafter, to subscribe for and purchase from Biotricity, Inc. a Nevada corporation , up to shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 . Definitions . In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicate...",
"Letter re: Registration Statement on Form S-3",
"Biotricity Prices $15 Million Underwritten Public Offering of Common Stock and Listing on the Nasdaq Capital Market REDWOOD CITY, CA / ACCESSWIRE / August 26, 2021 / Biotricity, Inc. , a medical diagnostic and consumer healthcare technology company, today announced the pricing of an underwritten public offering of 5,000,000 shares of common stock of the Company, at a price of $3.00 per share for total gross proceeds to the Company of approximately $15 million. In addition, the Company has granted the underwriter of the offering a 30-day option to purchase an additional 750,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The closing of the offering is expected to occur on August 30, 2021, subject to customary closing conditions. In conne...",
"Biotricity Closes $15 Million Underwritten Public Offering Completes Nasdaq Uplist REDWOOD CITY, CA / ACCESSWIRE / August 30, 2021 / Biotricity, Inc. , a medical diagnostic and consumer healthcare technology company, today announced the closing of an underwritten public offering of 5,000,000 shares of common stock of the Company for total gross proceeds to the Company of approximately $15 million. The offering was priced at $3.00 per share. In addition, the Company has granted the underwriter of the offering a 30-day option to purchase an additional 750,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The Company intends to use the net proceeds from this offering for general corporate purposes, including, but not limited to, working capi..." |
|
| 08/17/2021 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 07/08/2021 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits |
| 06/17/2021 |
8-K
| Quarterly results |
| 04/15/2021 |
8-K
| Quarterly results |
| 02/12/2021 |
8-K
| Quarterly results |
| 01/22/2021 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 12/31/2020 |
8-K
| Quarterly results |
| 11/20/2020 |
8-K
| Quarterly results |
| 08/13/2020 |
8-K
| Quarterly results |
| 08/06/2020 |
8-K
| Quarterly results |
| 07/13/2020 |
8-K
| Quarterly results |
| 06/26/2020 |
8-K
| Quarterly results |
|
|
|